ID

17916

Beschreibung

The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00065325

Link

https://clinicaltrials.gov/show/NCT00065325

Stichworte

Versionen (1)
  1. 09.10.16 09.10.16 -
Hochgeladen am

9. Oktober 2016

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Locally Advanced Breast Cancer NCT00065325

Englisch

Eligibility Locally Advanced Breast Cancer NCT00065325

1 Formulare  
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
biopsy confirmation of breast cancer
Beschreibung

Breast Carcinoma | Biopsy

Datentyp

boolean

Alias
UMLS CUI [1]
C0678222
UMLS CUI [2]
C0005558
breast cancer has continued to grow after having received treatment with an aromatase inhibitor
Beschreibung

Therapeutic procedure Breast Carcinoma | Aromatase Inhibitor | Disease Progression

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C0678222
UMLS CUI [2]
C0593802
UMLS CUI [3]
C0242656
postmenopausal women defined as a women who has stopped having menstrual periods
Beschreibung

Postmenopausal state | Periods have stopped

Datentyp

boolean

Alias
UMLS CUI [1]
C0232970
UMLS CUI [2]
C0425957
evidence of hormone sensitivity
Beschreibung

hormone sensitivity Evidence of

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0920555
UMLS CUI [1,2]
C0332120
written informed consent to participate in the trial
Beschreibung

Informed Consent

Datentyp

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
previous treatment with faslodex (fulvestrant) or aromasin (exemestane)
Beschreibung

Faslodex | fulvestrant | Aromasin | exemestane

Datentyp

boolean

Alias
UMLS CUI [1]
C0701491
UMLS CUI [2]
C0935916
UMLS CUI [3]
C0876723
UMLS CUI [4]
C0851344
any hormonal therapy used to modify the course of an additional medical condition after prior treatment with a non-steroidal aromatase inhibitor
Beschreibung

Hormone Therapy Other medical condition Changing | Non-Steroidal Aromatase Inhibitor

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0279025
UMLS CUI [1,2]
C3843040
UMLS CUI [1,3]
C0392747
UMLS CUI [2]
C1518386
treatment with an investigational or non-approved drug within one month
Beschreibung

Investigational New Drugs | Illicit Drugs

Datentyp

boolean

Alias
UMLS CUI [1]
C0013230
UMLS CUI [2]
C0086190
an existing serious disease, illness, or condition that will prevent participation or compliance with study procedures
Beschreibung

Disease Serious Preventing participation | Disease Serious Preventing Protocol Compliance | Condition Preventing participation | Condition Preventing Protocol Compliance

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C0205404
UMLS CUI [1,3]
C1292733
UMLS CUI [1,4]
C0679823
UMLS CUI [2,1]
C0012634
UMLS CUI [2,2]
C0205404
UMLS CUI [2,3]
C1292733
UMLS CUI [2,4]
C0525058
UMLS CUI [3,1]
C0348080
UMLS CUI [3,2]
C1292733
UMLS CUI [3,3]
C0679823
UMLS CUI [4,1]
C0348080
UMLS CUI [4,2]
C1292733
UMLS CUI [4,3]
C0525058
a history of allergies to any active or inactive ingredients of faslodex or exemestane (i.e. castor oil or mannitol)
Beschreibung

Hypersensitivity Faslodex Ingredient | Hypersensitivity exemestane Ingredient | Hypersensitivity Castor Oil | Hypersensitivity Mannitol

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0701491
UMLS CUI [1,3]
C1550600
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0851344
UMLS CUI [2,3]
C1550600
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C0007343
UMLS CUI [4,1]
C0020517
UMLS CUI [4,2]
C0024730
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Locally Advanced Breast Cancer NCT00065325

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Breast Carcinoma | Biopsy
Item
biopsy confirmation of breast cancer
boolean
C0678222 (UMLS CUI [1])
C0005558 (UMLS CUI [2])
Therapeutic procedure Breast Carcinoma | Aromatase Inhibitor | Disease Progression
Item
breast cancer has continued to grow after having received treatment with an aromatase inhibitor
boolean
C0087111 (UMLS CUI [1,1])
C0678222 (UMLS CUI [1,2])
C0593802 (UMLS CUI [2])
C0242656 (UMLS CUI [3])
Postmenopausal state | Periods have stopped
Item
postmenopausal women defined as a women who has stopped having menstrual periods
boolean
C0232970 (UMLS CUI [1])
C0425957 (UMLS CUI [2])
hormone sensitivity Evidence of
Item
evidence of hormone sensitivity
boolean
C0920555 (UMLS CUI [1,1])
C0332120 (UMLS CUI [1,2])
Informed Consent
Item
written informed consent to participate in the trial
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Faslodex | fulvestrant | Aromasin | exemestane
Item
previous treatment with faslodex (fulvestrant) or aromasin (exemestane)
boolean
C0701491 (UMLS CUI [1])
C0935916 (UMLS CUI [2])
C0876723 (UMLS CUI [3])
C0851344 (UMLS CUI [4])
Hormone Therapy Other medical condition Changing | Non-Steroidal Aromatase Inhibitor
Item
any hormonal therapy used to modify the course of an additional medical condition after prior treatment with a non-steroidal aromatase inhibitor
boolean
C0279025 (UMLS CUI [1,1])
C3843040 (UMLS CUI [1,2])
C0392747 (UMLS CUI [1,3])
C1518386 (UMLS CUI [2])
Investigational New Drugs | Illicit Drugs
Item
treatment with an investigational or non-approved drug within one month
boolean
C0013230 (UMLS CUI [1])
C0086190 (UMLS CUI [2])
Disease Serious Preventing participation | Disease Serious Preventing Protocol Compliance | Condition Preventing participation | Condition Preventing Protocol Compliance
Item
an existing serious disease, illness, or condition that will prevent participation or compliance with study procedures
boolean
C0012634 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C1292733 (UMLS CUI [1,3])
C0679823 (UMLS CUI [1,4])
C0012634 (UMLS CUI [2,1])
C0205404 (UMLS CUI [2,2])
C1292733 (UMLS CUI [2,3])
C0525058 (UMLS CUI [2,4])
C0348080 (UMLS CUI [3,1])
C1292733 (UMLS CUI [3,2])
C0679823 (UMLS CUI [3,3])
C0348080 (UMLS CUI [4,1])
C1292733 (UMLS CUI [4,2])
C0525058 (UMLS CUI [4,3])
Hypersensitivity Faslodex Ingredient | Hypersensitivity exemestane Ingredient | Hypersensitivity Castor Oil | Hypersensitivity Mannitol
Item
a history of allergies to any active or inactive ingredients of faslodex or exemestane (i.e. castor oil or mannitol)
boolean
C0020517 (UMLS CUI [1,1])
C0701491 (UMLS CUI [1,2])
C1550600 (UMLS CUI [1,3])
C0020517 (UMLS CUI [2,1])
C0851344 (UMLS CUI [2,2])
C1550600 (UMLS CUI [2,3])
C0020517 (UMLS CUI [3,1])
C0007343 (UMLS CUI [3,2])
C0020517 (UMLS CUI [4,1])
C0024730 (UMLS CUI [4,2])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video